GlassScriptPhysician profile
Nam S Cho
NPI 1255339263
$18,738.34
in general payments reported to CMS, 2019-2025
29 companies · $3,835 in 2025
The $3,835 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,872 · 2020: $1,174 · 2021: $3,176 · 2022: $2,589 · 2023: $3,481 · 2024: $1,611 · 2025: $3,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,812 · Travel and Lodging: $3,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,812.26 |
| Travel and Lodging | $3,115.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $7,586.70 | 2019-2025 | Pascal, Sapien 3 Ultra Resilia, Evoque |
| Abbott Laboratories | $3,863.33 | 2019-2025 | Mitraclip, Aveir, Esprit |
| Boston Scientific Corporation | $2,438.05 | 2019-2025 | Watchman Flx, Watchman Access System, Varithena Administration Pack |
| Medtronic, INC. | $1,266.25 | 2021-2025 | Corevalve Evolut R, Tyrx, Linq II |
| Medtronic Vascular, INC. | $808.62 | 2019-2020 | |
| Shockwave Medical, INC | $722.62 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Teleflex LLC | $372.94 | 2021-2024 | Manta, Turnpike |
| Novartis Pharmaceuticals Corporation | $368.03 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $231.12 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $168.05 | 2019-2024 | Eliquis, Camzyos |
| Pfizer INC. | $164.28 | 2021-2025 | |
| Angiodynamics, INC. | $149.17 | 2022-2025 | Alphavac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.78 | 2019-2024 | Jardiance |
| Amgen INC. | $114.17 | 2022-2025 | Repatha |
| Biosense Webster, INC. | $49.19 | 2023-2025 | Carto 3, Nuvision Ice Catheter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $43.57 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $38.24 | 2023 | Andexxa, Brilinta |
| Alnylam Pharmaceuticals INC. | $32.72 | 2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $27.16 | 2023 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $25.05 | 2019 | |
| Lundbeck LLC | $23.02 | 2019 | |
| Cardiovascular Systems INC. | $19.68 | 2019 | |
| Astellas Pharma US INC | $18.57 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.95 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.36 | 2023 | |
| Alexion Pharmaceuticals, INC. | $13.12 | 2019 | |
| Inari Medical, INC. | $12.93 | 2020 | |
| Getinge USA Sales, LLC | $12.84 | 2021 | |
| Irhythm Technologies, INC. | $11.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nam Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.